Sorafenib versus Lenvatinib Causes Stronger Oxidative Damage to Membrane Lipids in Noncancerous Tissues of the Thyroid, Liver, and Kidney: Effective Protection by Melatonin and Indole-3-Propionic Acid

Sorafenib versus Lenvatinib Causes Stronger Oxidative Damage to Membrane Lipids in Noncancerous Tissues of the Thyroid, Liver, and Kidney: Effective Protection by Melatonin and Indole-3-Propionic Acid

Sorafenib and lenvatinib are multi-targeted tyrosine kinase inhibitors which are currently approved to treat advanced hepatocellular carcinoma, renal cell carcinoma and radioiodine-refractory differentiated thyroid carcinoma. However this treatment is often limited due to common adverse events which...

Full description

Bibliographic Details
Main Authors: Jan Stępniak, Joanna Krawczyk-Lipiec, Andrzej Lewiński, Małgorzata Karbownik-Lewińska
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Biomedicines
Subjects:
sorafenib
lenvatinib
lipid peroxidation
melatonin
indole-3-propionic acid
Online Access:https://www.mdpi.com/2227-9059/10/11/2890

Similar Items

Similar Items